Skip to content

Intra Testicular Artery Injection of Bone Marrow Stem Cell in Management of Azoospermia

Intra Testicular Artery Injection of Bone Marrow Stem Cell in Management of Azoospermia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02008799
Enrollment
20
Registered
2013-12-11
Start date
2013-01-31
Completion date
2016-12-31
Last updated
2015-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Azoospermia

Keywords

Stem cell, infertility, Azoospermia

Brief summary

Azoospermia due to low sperm production (non-obstructive azoospermia) affects approximately 1% of the male population and 10% of men who seek fertility evaluation. Testis biopsy reveals that these men have Sertoli cell-only pattern, maturation arrest, or hypospermatogenesis. Until recently, it was assumed that men with non-obstructive azoospermia were untreatable. Indeed, these patients were often referred to as being sterile or having testicular failure. We start to use stem cell in treatment of such patients by injecting the stem cell at the testis and the testicular artery in one group and at the testis only in other group

Interventions

PROCEDUREBone marrow stem cell injection

Injection should be in testis and testicular artery

Sponsors

Man Clinic for Andrology, Male Infertility and Sexual Dysfunction
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

\- Azoospermia

Exclusion criteria

\- Absent or surgical removed testes

Design outcomes

Primary

MeasureTime frameDescription
Semen AnalysisThree to six monthsAfter stem cell injection by three to six months we evaluate the outcome by semen analysis

Secondary

MeasureTime frameDescription
Inhibin B HormoneThree to six monthsIf semen analysis still azoo we do Inhibin B Hormone

Countries

Egypt

Contacts

Primary ContactKhaled A Gadalla, MD
Khaledgadalla@gmail.com20222725025

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026